Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb has entered into a strategic partnership with WuXi PharmaTech to conduct stability studies of new chemical entities. The agreement is in line with Bristol-Myers plans to support its global marketing applications.
Subscribe to our email newsletter
Under the partnership, a fully cGMP-compliant analytical testing facility will be developed in Shanghai in 25,000-square-foot area by WuXi which will build, equip and operate the facility. Stability samples will be stored and tested in the facility where other services will also be provided for Bristol-Myers.
WuXi will provide analytical testing, metrology, pharmaceutical science, quality assurance, sample management, stability testing and stability data reporting for global dossier submissions by Bristol-Myers.
WuXi PharmaTech chairman and CEO Ge Li said the company will continue to help Bristol-Myers to improve its R&D productivity with innovation-driven, cost-effective and fully integrated R&D service platform.
Bristol-Myers Squibb Non-Clinical Development senior vice president Mark Powell said the partnership will expand the relationship with WuXi and strengthens its presence in China.